Table 1.
Clinical and pathological features
| Characteristics | Study population (n = 123) |
|---|---|
| Age (years) | 65.3 (49.3–77.7) |
| Prostate volume (ml) | 38.7 (15–95) |
| Pre-operative PSA (ng ml−1) | 11.4 (1.4–200) |
| Clinical stage | |
| cT1 | 60 (48.8%) |
| cT2 | 51 (41.5%) |
| cT3–cT4 | 12 (9.8%) |
| Gleason score on surgical specimen | |
| 6 | 22 (17.9%) |
| 3+4 (7) | 54 (43.9%) |
| 4+3 (7) | 20 (16.3%) |
| 8 | 13 (10.6%) |
| 9 | 14 (11.4%) |
| Histological tumour volume (ml) | 4.8 (0.3–47.5) |
| D'Amico risk classification | |
| Low risk | 15 (12.2%) |
| Medium risk | 74 (60.2%) |
| High risk | 34 (27.8%) |
PSA, prostate-specific antigen.
Data are means (ranges) or counts (percentages).